Framnes DeBoer S, Bakke E, Yalamanchili S, Peterson H, Sandoval D, Seeley R, et al. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor. Am J Physiol Endocrinol Metab. 2020;318:E62-E71 pubmed publisher

Winters S, Ghooray D, Yang R, Holmes J, O Brien A, Morgan J, et al. Dopamine-2 receptor activation suppresses PACAP expression in gonadotrophs. Endocrinology. 2014;155:2647-57 pubmed publisher

Li H, Wei C, Gao J, Bai S, Li H, Zhao Y, et al. Mediation of dopamine D2 receptors activation in post-conditioning-attenuated cardiomyocyte apoptosis. Exp Cell Res. 2014;323:118-30 pubmed publisher

Peixoto Silva N, Conceição E, Carvalho J, Lima N, Nogueira Neto J, de Oliveira E, et al. Does bromocriptine play a role in decreasing oxidative stress for early weaned programmed obesity?. Life Sci. 2014;95:14-21 pubmed publisher

Saejong R, Dangrat C, Techatrisak K, Angsuwatthana S, Rattanachaiyanont M, Tanmahasamut P. Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital. J Med Assoc Thai. 2013;96:1247-56 pubmed

Goth M. [Drug therapy for acromegaly]. Orv Hetil. 2013;154:1527-34 pubmed publisher

Boaventura G, Casimiro Lopes G, Pazos Moura C, Oliveira E, Lisboa P, Moura E. Effects of running wheel training on adult obese rats programmed by maternal prolactin inhibition. J Endocrinol. 2013;219:29-37 pubmed publisher

Wongdee K, Thonapan N, Saengamnart W, Krishnamra N, Charoenphandhu N. Bromocriptine modulates the expression of PTHrP receptor, Indian hedgehog, and Runx2 proteins in the growth plate of lactating rats. Mol Cell Biochem. 2013;381:191-9 pubmed publisher

Torner L, Tinajero E, Lajud N, Quintanar Stephano A, Olvera Cortés E. Hyperprolactinemia impairs object recognition without altering spatial learning in male rats. Behav Brain Res. 2013;252:32-9 pubmed publisher

Taniguchi R, Nakagawasai O, Tan No K, Yamadera F, Nemoto W, Sato S, et al. Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. Biosci Biotechnol Biochem. 2013;77:266-70 pubmed

Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, et al. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Intern Med. 2013;52:325-32 pubmed

Lou X, Wu Z, Zhang Y. Bromocriptine-induced brainstem angulation in a patient with invasive prolactinoma. J Clin Endocrinol Metab. 2013;98:867-8 pubmed publisher

Lyzogub V, Dolynna O, Bogdan T, Sobol V. [State of the dopamine system activity, as one of factors for the development of arterial hypertension and obesity]. Lik Sprava. 2012;:41-7 pubmed

Garber A, Blonde L, Bloomgarden Z, Handelsman Y, Dagogo Jack S. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013;19:100-6 pubmed publisher

Catli G, Abaci A, Altincik A, Demir K, Can S, Buyukgebiz A, et al. Hyperprolactinemia in children: clinical features and long-term results. J Pediatr Endocrinol Metab. 2012;25:1123-8 pubmed publisher

Gaziano J, Cincotta A, Vinik A, Blonde L, Bohannon N, Scranton R. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc. 2012;1:e002279 pubmed publisher

Mukherjee R, Yun J. Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on ?2-adrenergic receptor in 3T3-L1 adipocyte cells. Mol Biol Rep. 2013;40:3783-92 pubmed publisher

Grinkova Y, Denisov I, McLean M, Sligar S. Oxidase uncoupling in heme monooxygenases: human cytochrome P450 CYP3A4 in Nanodiscs. Biochem Biophys Res Commun. 2013;430:1223-7 pubmed publisher

Nade V, Kawale L, Todmal U, Tajanpure A. Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats. Indian J Pharmacol. 2012;44:688-93 pubmed publisher

Bian J, Liu C, Sun X, Deng C, Huang Y, Ye Y. [Efficacy of compound xuanju capsule combined with bromocriptine on hyperprolactinemia-induced erectile dysfunction]. Zhonghua Nan Ke Xue. 2012;18:1023-7 pubmed

Vinik A, Cincotta A, Scranton R, Bohannon N, Ezrokhi M, Gaziano J. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18:931-43 pubmed publisher

Beltrame A, Serafini P, Motta E, Soares Júnior J, Baracat E. The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecol Endocrinol. 2013;29:201-4 pubmed publisher

Ratner L, Gonzalez B, Ahtiainen P, Di Giorgio N, Poutanen M, Calandra R, et al. Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility. Endocrinology. 2012;153:5980-92 pubmed publisher

Ginther O, Santos V, Mir R, Beg M. Role of LH in the progesterone increase during the bromocriptine-induced prolactin decrease in heifers. Theriogenology. 2012;78:1969-76 pubmed publisher

Ginther O, Pinaffi F, Rodriguez M, Duarte L, Beg M. Stimulatory effect of PGF2α on PRL based on experimental inhibition of each hormone in mares. Theriogenology. 2012;78:1960-8 pubmed publisher

Bell D. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. Postgrad Med. 2012;124:121-35 pubmed publisher

Sykora C, Amor M, Schlenker E. Age and hypothyroidism affect dopamine modulation of breathing and D₂ receptor levels. Respir Physiol Neurobiol. 2013;185:257-64 pubmed publisher

Burton T, Le Nestour E, Bancroft T, Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary. 2013;16:354-62 pubmed publisher

Lyzogub V, Sobol V, Dolynna O, Kuz mins ka L. [Effect of combined treatment with dopamine receptor agonists and antagonists of aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity]. Lik Sprava. 2012;:63-8 pubmed

Oladapo O, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev. 2012;:CD005937 pubmed publisher

Nio Kobayashi J, Iwanaga T. Galectin-1 and galectin-3 in the corpus luteum of mice are differentially regulated by prolactin and prostaglandin F2?. Reproduction. 2012;144:617-24 pubmed publisher

Vale F, Deukmedjian A, Hann S, Shah V, Morrison A. Medically treated prolactin-secreting pituitary adenomas: when should we operate?. Br J Neurosurg. 2013;27:56-62 pubmed publisher

Kim I, Park S, Park J, Lee S, Hong S, Reed J. Cyclosporine A and bromocriptine attenuate cell death mediated by intracellular calcium mobilization. BMB Rep. 2012;45:482-7 pubmed publisher

Kang S, Kim M, Shin I, Park D, Sohn J, Yoon Y. Bromocriptine for control of hyperthermia in a patient with mixed autonomic hyperactivity after neurosurgery: a case report. J Korean Med Sci. 2012;27:965-8 pubmed publisher

Schroeter M, Unsöld B, Holke K, Schillinger W. Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump. Clin Res Cardiol. 2013;102:155-7 pubmed publisher

Wang D, Wong H, Zhang L, McAlonan G, Wang X, Sze S, et al. Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:332-8 pubmed publisher

Matsuda M. [Bromocriptine]. Nihon Rinsho. 2012;70 Suppl 3:734-9 pubmed

Geurts M, Hermans E, Cumps J, Maloteaux J. Dopamine receptor-modulated [35S]GTPgammaS binding in striatum of 6-hydroxydopamine-lesioned rats. Brain Res. 1999;841:135-42 pubmed

Zhang Y, Scislowski P, Prevelige R, Phaneuf S, Cincotta A. Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. Metabolism. 1999;48:1033-40 pubmed

Velasco M, Luchsinger A. Dopamine: pharmacologic and therapeutic aspects. Am J Ther. 1998;5:37-43 pubmed

Perachon S, Schwartz J, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol. 1999;366:293-300 pubmed